ABT-450 Ritonavir

In this phase 3 trial researchers have evaluated the efficacy and safety of the Interferon-free combination of ABT-450 with Ritonavir...


Interferon-containing regimens for the treatment of hepatitis C virus ( HCV ) infection are associated with increased toxic effects in...


The Interferon-free combination of the protease inhibitor ABT-450 with Ritonavir ( ABT-450/r ) and the NS5A inhibitor Ombitasvir ( also...


Results from studies in chronic hepatitis C patients with human immunodeficiency virus type 1 ( HIV-1 ) co-infection ( TURQUOISE-I...


Interferon-containing regimens for the treatment of hepatitis C virus ( HCV ) infection are associated with increased toxic effects in...


An Interferon-free combination of the protease inhibitor ABT-450 with Ritonavir ( ABT-450/r ), the nonnucleoside polymerase inhibitor ABT-333, and Ribavirin...


The first detailed results from pivotal phase III study, PEARL-III, were presented as part of the 21st Conference on Retroviruses...


AbbVie has announced the completion of its phase III clinical program and released results of four additional studies designed to...


The new Interferon-free, all-oral, three direct-acting-antiviral ( 3D ) treatment regimen in development by AbbVie has achieved very high rates...


In the 631-patient SAPPHIRE-I study, patients new to therapy receiving 12 weeks of 3D regimen achieved a sustained virologic response...


The approval of two hepatitis C virus ( HCV ) protease inhibitors by the FDA ( Food and Drug Administration...


There is a need for Interferon-free treatment regimens for hepatitis C virus ( HCV ) infection. The goal of a...